Shigellosis is a clinical syndrome resulting from invasion of the epithelium lining the terminal ileum, colon, and rectum by Shigella species, and is the principal cause of bacillary diarrhoea in humans [3][1]. These intestinal pathogens require only a very low infectious dose to establish illness [2][4].
Aperçu de la maladie
Bactérienne Informations étayées par des preuves EN 5/7 sections · FR 5/7 sections Mis à jour le Oct 23, 2026
Shigellosis is a clinical syndrome caused by Shigella invasion of the distal intestinal epithelium, occurring worldwide across all age groups [1]. The greatest disease burden falls on young children in low- and middle-income settings, while high-income countries see concentrated risk among travelers and gbMSM [2][1]. Sexual transmission among men who have sex with men represents an emerging public-health concern [2].
Lire le profil clinique et épidémiologique complet 6
Manifestations range from acute watery diarrhoea to fulminant dysentery with frequent scant bloody stools, fever, prostration, and abdominal cramps [1]. The classic descending infection begins with few large-volume stools and progresses to many small-volume bloody, mucoid stools [4]. Severe diarrhoea, fever, or bloody stools with abundant faecal leukocytes should raise suspicion of shigellosis [4].
Infections occur globally and across all ages, but endemic disease among children aged 1–4 years in low- and middle-income countries constitutes most of the burden [1]. In high-income settings, international travelers and gbMSM are the main affected groups [2]. Approximately 164,000 annual deaths are attributable to shigellosis despite reductions in mortality over recent decades [1].
Shigellae spread efficiently through person-to-person contact, with as few as 200 viable organisms sufficient to cause disease in susceptible persons [4]. Sexual contact, particularly among gbMSM, is a recognized route, facilitated by the low infectious dose and possible asymptomatic carriage [2]. The dynamics of sexual transmission are not yet fully understood [2].
To reduce sexual transmission, at-risk groups should adopt less risky sexual behaviors, use protective measures, clean sex toys thoroughly, and maintain good personal hygiene [2]. Partners with diarrhoea should avoid sexual contact during illness and for at least 1–2 weeks after symptom resolution, refraining from oral–anal contact for 4–6 weeks [2]. Raising awareness among clinicians and at-risk populations about sexual transmission is essential for appropriate counseling [2].
- 1 Kotloff KL et al. Shigellosis. Lancet. 2018 Feb 24. PMID: 29254859. doi: 10.1016/S0140-6736(17)33296-8. PubMed: https://pubmed.ncbi.nlm.nih.gov/29254859/
- 2 Pirš M et al. Sexually transmitted shigellosis. Acta Dermatovenerol Alp Pannonica Adriat. 2024 Dec. PMID: 39707895. PubMed: https://pubmed.ncbi.nlm.nih.gov/39707895/
- 3 Pakbin B et al. Molecular Mechanisms of Shigella Pathogenesis; Recent Advances. Int J Mol Sci. 2023 Jan 26. PMID: 36768771. doi: 10.3390/ijms24032448. PubMed: https://pubmed.ncbi.nlm.nih.gov/36768771/
- 4 DuPont HL et al. Shigella. Infect Dis Clin North Am. 1988 Sep. PMID: 3074117. PubMed: https://pubmed.ncbi.nlm.nih.gov/3074117/
Chargement des données actuelles…
Tendances nationales
Choisissez le pays, la source et la mesure ; chaque courbe conserve sa période et sa définition de déclaration.
Chargement des données…
Couverture des données
Pays et régions déclarants
La carte montre la couverture déclarée. Choisissez une mesure ou ouvrez un lieu coloré pour consulter ses données.
Chargement des données actuelles…
Profil de surveillance
Saisonnalité du pays sélectionné
Consultez les valeurs mensuelles d’un pays par année. Les cases vides indiquent une valeur non publiée.
Radar de recherche
Recherches récentes associées
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial
The Lancet Infectious Diseases
Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study
PLOS Medicine
High levels of domestic transmission and drug resistance –analysis of national surveillance data for shigellosis, the Netherlands, 2018 to 2024
Eurosurveillance
Burden of Shigella infection in children under five years living in a peri-urban area of Ouagadougou, Burkina Faso: A community-based cohort study
PLOS Neglected Tropical Diseases
Qualification of a high-throughput luminescence-based Serum Bactericidal Activity assay to assess the functionality of human sera against five Shigella serotypes
Vaccine
5 publications associées sur 43 affichées.
Les liens bibliographiques servent à découvrir des travaux et ne modifient ni ne valident la série de surveillance ci-dessus.
Chargement des alertes officielles…
Téléchargement et méthodes
Choisissez une période et téléchargez les fichiers CSV, JSON ou XLSX.